论文部分内容阅读
α-干扰素第二阶段的试验已经完成,试验清楚地表明,α-干扰素有抗某些恶性肿瘤的作用。与当前使用的其它抗肿瘤药物相比,该药的作用程度证明其在临床应用中是有效的。一些病人对干扰素反应良好,另一些病人出现长时间的持续性反应。除临床上的作用外,干扰素为一种典型的生物反应调节剂。就这一作用而言,此项研究工作制剂为最近已进入第一阶段临床试验的其他生物学制剂提供了一个范例。如果其它免疫调节肽和单克隆抗体具有与干扰素相同的免疫调节作用和临床作用,那么这种新的抗肿瘤疗法(生物学疗法)将实现20年前所预言的用免疫学方法治疗某些癌症的设想。
The second phase of alpha-interferon testing has been completed and the trial clearly shows that alpha-interferon has anti-tumor effects. Compared with other anti-tumor drugs currently in use, the extent of its action proves that it is effective in clinical applications. Some patients responded well to interferon, while others experienced prolonged, sustained reactions. In addition to its clinical role, interferon is a typical biological response modifier. For this role, this research work formulation provides an example of other biological agents that have recently entered Phase I clinical trials. If other immunomodulatory peptides and monoclonal antibodies have the same immunomodulatory and clinical effects as interferons, this new antitumor therapy (biological therapy) will achieve some of the immunological methods that were foreseen 20 years ago The idea of cancer.